CMMB Valuation

Chemomab Therapeutics Ltd

Add to Watchlist

Advanced Chart

1.100

-0.02(-1.786%)1D

Overview
Forecast
Valuation
Earnings

CMMB Relative Valuation

CMMB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CMMB is overvalued; if below, it's undervalued.

Historical Valuation

Chemomab Therapeutics Ltd (CMMB) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -35.73. The fair price of Chemomab Therapeutics Ltd (CMMB) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：1.10

Fair

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

2.03

P/B

Median3y

1.14

Median5y

1.40

0.00

FCF Yield

Median3y

-111.04

Median5y

-81.53

Competitors Valuation Multiple

The average P/S ratio for CMMB's competitors is 7.70, providing a benchmark for relative valuation. Chemomab Therapeutics Ltd Corp (CMMB) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

CMMB.O

Chemomab Therapeutics Ltd

Loss

Average P/S: 7.70

21.08M